Brian Daniels MD

Brian Daniels MD General Information

Biography

Dr. Brian Daniels serves as a Board Member, Member of the Remuneration Committee, and Member of the Research & Development Committee at Novo Nordisk. He serves as Board Member & Member of the Innovation & Development Committee at CSL. He serves as Board Member at Neurogastrx. He served as Board Member at RareCyte. He served as Chairman at Artiva Biotherapeutics and Board Member at Inipharm Inc. He served as a Board Member at Nohla Therapeutics. He served as Acting Chief Medical Officer at Expansion Therapeutics. He serves as a Venture Partner at 5AM Ventures. He joined 5AM Ventures in 2014 as a Venture Partner. Prior to his joining, he spent over two decades in clinical drug development including the last ten years as the leader of Development and Medical Affairs at Bristol-Myers Squibb. He directed the development of numerous innovative medicines that have contributed to improvements for patients across a range of serious diseases. These include ORENCIA and NULOJIX in immunology/transplant, REYATAZ, DAKLINZA, and BARACLUDE in virology, ONGLYZA, FARXIGA, and MYALEPT in metabolics, ELIQUIS in CV and YERVOY, OPDIVO, SPRYCEL and IXEMPRA in oncology. He also served as a Board Member at Spyryx Biosciences and served on the Scientific Advisory Board of Novira. He received B.S. and M.S. degrees from MIT and his M.D. from Washington University in St. Louis. He trained in internal medicine at New York Hospital and Rheumatology/Immunology at UCSF.